- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03957369
Primary Resistance in HIV Patients in Colombia
Prevalence of NRTI, NNRTI, PI and INSTI Primary Resistance-Associated Mutations of Adult Naïve HIV-1 Seropositive Patients in Colombia
Study Overview
Status
Conditions
Detailed Description
The number of patients and sample size:
The proportion formula for finite populations was used to determine the sample size (with appropriate confidence intervals) needed to find the prevalence of RAMs in naive HIV population from Colombia.
As shown below, estimating 20% of loss, the sample size will be 500 study subjects considering a CI 97%.
The sample size is estimated in 501 patients, considering 1% or less of the probability of finding pre-treatment resistance-associated mutations affecting integrase inhibitors, a CI of 97%, and 20% of blood samples loss or not processable.
Sample selection:
The investigators chose 12 cities (Bogotá, Cali, Medellín, Barranquilla, Montería, Cartagena, Bucaramanga, Cúcuta, Pereira, Villavicencio, Pasto, and Florencia) in which the majority of the HIV population is found in Colombia, accounting for around 80% according to data from the High-Cost Account (CAC, in its Spanish acronym) 2016. Moreover, this allows the selection of patients with diverse races or ethnic groups.
The healthcare provider institutions (Instituciones Prestadoras de Salud - IPS in Spanish) with integral HIV care programs in accordance with the quality and service requirements demanded by the Colombian Ministry of Social Protection.
The sample will be selected as follows:
- Patients will be chosen based on the opportunity to attend the healthcare provider institutions (IPS) if they meet the inclusion criteria.
- Treating physicians in charge of HIV care in the healthcare provider institutions will invite patients to participate upon explanation of the nature, purposes, and benefits of the study. If a patient agrees to participate, informed consent will be asked. Once this consent is given and the respective written form is signed, the collection of data will be collected and a blood sample will be drawn.
- If a patient has signed the written informed consent form but does not provide the blood sample, he or she will be excluded and another patient will be expected to be included in order to complete the sample size calculated for the study.
Data collection:
A unique identification code, assigned to each patient, will be registered in the case report forms and in the laboratory report. The research group will keep the absolute privacy of collected data that relates the patient's name with the identification code.
Procedures for primary resistance-associated mutations determination in the blood samples:
Genotyping sequencing will be performed using traditional and ultradeep sequencing techniques in plasma samples by Sanger and Next-Generation Sequencing, respectively. Stanford database analysis criteria will be used to compare the performance of these techniques. Both techniques will be performed in all samples.
Plasma samples will be sent for processing for both techniques at Centro de Investigación en Enfermedades Infecciosas - CIENI in Mexico City.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Contact
- Name: ERNESTO MARTINEZ, MD
- Phone Number: +573164484799
- Email: emarbui@gmail.com
Study Contact Backup
- Name: ERNESTO M B., RPT
- Phone Number: +57 3006005299
- Email: Emarbui@gmail.com
Study Locations
-
-
Valle
-
Cali, Valle, Colombia, 760043
- Recruiting
- REVIVA, Red de VIH del Valle del Cauca
-
Contact:
- ERNESTO MARTINEZ, MD
- Phone Number: +57 3164484799
- Email: emarbui@gmail.com
-
Contact:
- LUZ M SAÑUDO, RPT
- Phone Number: +57 3006005299
- Email: luzma56@gmail.com
-
Sub-Investigator:
- JOSE M OÑATE, MD
-
Sub-Investigator:
- JOSE F GARCÍA-GOEZ, MD
-
Sub-Investigator:
- WILLIAM LENIS, MD
-
Sub-Investigator:
- LUISA C CONSUELO, MD, MSc
-
Sub-Investigator:
- JORGE ALVAREZ, MD
-
Sub-Investigator:
- ANDRES F ZAPATA, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Naive HIV-positive individuals aged 18 years or older.
- Consent to participate in the research.
Exclusion Criteria:
1. Patients with any type of antiretroviral exposure
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Cross-Sectional
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Adult naive HIV positive individuals
HIV-diagnosed subjects, older than 18 years, with no prior exposure to antiretroviral drugs.
|
After signing informed consent, we will collect whole blood for HIV genotyping in plasma HIV-1 RNA for testing of resistance-associated mutations to reverse transcriptase, protease, and integrase enzymes.
Other Names:
After signing informed consent, we will collect whole blood for HIV genotyping in plasma HIV-1 RNA for testing of resistance-associated mutations to reverse transcriptase, protease, and integrase enzymes.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Prevalence of primary HIV drug associated resistance in Colombia
Time Frame: November 2019 - December 2020
|
Prevalence estimated by nationwide sampling of adults HIV positive individuals
|
November 2019 - December 2020
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Outcomes by demographic characteristics
Time Frame: November 2019 - September 2022
|
Estimate HIV drug resistance by age, sex, race and ethnic groups overall and in each of the different included Colombian regions and 12 Colombian cities
|
November 2019 - September 2022
|
Resistance to integrase
Time Frame: November 2019 - September 2022
|
Determine the presence of RAMs to integrase to correlate with primary resistance to integrase inhibitors in Colombia
|
November 2019 - September 2022
|
Correlate of HIV-1 sequencing by Sanger vs Next-Generation Sequencing techniques
Time Frame: November 2019 - September 2022
|
Compare the results from sequencing plasma HIV-1 RNA by both proposed techniques
|
November 2019 - September 2022
|
Collaborators and Investigators
Investigators
- Principal Investigator: ERNESTO MARTINEZ, Fundacion REVIVA, Red de VIH del Valle del Cauca
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 212167
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on HIV Infection
-
Erasmus Medical CenterNot yet recruitingHIV Infections | Hiv | HIV-1-infection | HIV I InfectionNetherlands
-
Sociedad Andaluza de Enfermedades InfecciosasConsejeria de Salud. Junta de Andalucia. SpainCompletedHIV Infection | HIV-1 InfectionSpain
-
Allegheny Singer Research Institute (also known...Active, not recruitingHIV Infections | HIV-1-infection | HIV I InfectionUnited States
-
Beckman Coulter, Inc.CompletedHIV I Infection | HIV-2 InfectionFrance
-
Rockefeller UniversityCompletedHIV Infection | Healthy Volunteers | HIV-1 InfectionUnited States
-
Erasmus Medical CenterRecruitingHIV Infections | HIV-1-infection | HIV-2 InfectionNetherlands
-
Erasmus Medical CenterActive, not recruitingHIV Infections | HIV-1-infection | HIV-2 InfectionNetherlands
-
AIDS Healthcare FoundationUniversity of California, Los AngelesCompleted
-
Merck Sharp & Dohme LLCCompleted
-
National Institute of Allergy and Infectious Diseases...CompletedHIV-1 Infection | HIV Antibodies | Neutralizing Antibody | Viral Load | Monoclonal AntibodyUnited States
Clinical Trials on HIV-1 plasma RNA Genotyping secuencing by Sanger technique
-
University of Alabama at BirminghamAdult AIDS Clinical Trials GroupCompleted